Ana Isabel Bocanegra

20PUBLICATIONS
46CO-AUTHORS
Molecular targetsHaematological tumoursPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Innate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Jul 19, 2024
PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets.

Luisa Chocarro, Ester Blanco, Leticia Fernandez-Rubio

|Jan 10, 2024
Oleuropein-driven reprogramming of the myeloid cell compartment to sensitise tumours to PD-1/PD-L1 blockade strategies.

Ester Blanco, Noelia Silva-Pilipich, Ana Bocanegra

|Oct 04, 2023
Circulating low density neutrophils are associated with resistance to anti-PD1 immunotherapy in squamous head and neck cancer.

Virginia Arrazubi, Saioa Goñi, Iranzu González-Borja

|Aug 10, 2023
Metabolic rewiring induced by ranolazine improves melanoma responses to targeted therapy and immunotherapy.

Marta Redondo-Muñoz, Francisco Javier Rodriguez-Baena, Paula Aldaz

|Jun 28, 2023
Current Indications and Future Landscape of Bispecific Antibodies for the Treatment of Lung Cancer.

Hugo Arasanz, Luisa Chocarro, Leticia Fernández-Rubio

|Jun 27, 2023
Plasma fractalkine contributes to systemic myeloid diversity and PD-L1/PD-1 blockade in lung cancer.

Ana Bocanegra, Gonzalo Fernández-Hinojal, Daniel Ajona

Pageof 4

Frequent Collaborators

16 joint publications

Hugo Arasanz

14 joint publications

Ester Blanco

13 joint publications

Luisa Chocarro

12 joint publications

David Escors